Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Semin Nucl Med. 2010 May;40(3):182-9. doi: 10.1053/j.semnuclmed.2009.12.004.

Immuno-positron emission tomography in cancer models.

Author information

  • 1Department of Molecular and Translational Medicine, Fox Chase Cancer Center, Philadelphia, PA, USA.

Abstract

Positron emission tomography (PET) is playing an increasingly important role in the diagnosis, staging, and monitoring response to treatment in a variety of cancers. Recent efforts have focused on immuno-PET, which uses antibody-based radiotracers, to image tumors based on expression of tumor-associated antigens. It is postulated that the specificity afforded by antibody targeting should both improve tumor detection and provide phenotypic information related to primary and metastatic lesions that will guide therapy decisions. Advances in antibody-engineering are providing the tools to develop antibody-based molecules with pharmacokinetic properties optimized for use as immuno-PET radiotracers. Coupled with technical advances in the design of PET scanners, immuno-PET holds promise to improve diagnostic imaging and to guide the use of targeted therapies. An overview of the preclinical immuno-PET studies in cancer models is reviewed here.

Copyright 2010 Elsevier Inc. All rights reserved.

PMID:
20350627
[PubMed - indexed for MEDLINE]
PMCID:
PMC2848398
Free PMC Article

Images from this publication.See all images (2)Free text

Figure 1
Figure 2
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk